<DOC>
	<DOC>NCT01492426</DOC>
	<brief_summary>The purpose of this study is to compare the effectiveness of BMS-790052 (Daclatasvir) and Telaprevir when given in combination with Peginterferon alfa-2a and Ribavirin in genotype 1b patients</brief_summary>
	<brief_title>Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description>Allocation: Randomized Stratified</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Key Participants chronically infected with hepatitis C virus (HCV) genotype 1a or 1b HCV RNA viral load ≥10,000 IU/mL No prior treatment including but not limited to interferon, ribavirin, and directacting antivirals No history of cirrhosis liver biopsy within 3 years or Fibroscan® within 1 year Body mass index of 18 to 35 kg/m^2 Negative for HIV and hepatitis B virus Key Evidence of decompensated liver disease Evidence of medical condition other than HCV contributing to chronic liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hepatitis C Virus</keyword>
</DOC>